Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost.
OBJECTIVE
The aim of this study was to report a case of cystoid macular edema (CME) in a pseudophakic patient after switching from latanoprost to BAK-free travoprost.


METHODS
This study is presented as an interventional case report.


RESULTS
Clinical examination showed the development of CME, proven by ocular coherence tomography, after institution of BAK-free travoprost in a patient that was previously treated with Latanoprost. Ocular signs and symptoms responded to stopping travoprost and treatment with topical prednisolone and non-steroidal anti-inflammatory medicines. The intraocular pressure was successfully controlled with brimonidine tartrate 0.15%.


CONCLUSIONS
CME is a known adverse effect of all prostaglandin analogs. However, our patient developed this complication after being switched from latanoprost to BAK-free travoprost. This may be due to exacerbation of a previously undiagnosed CME or to the ionic-buffered preservative system (sofZia) alone or in combination with travoprost unique to this product. It is prudent to exercise caution in the use of prostaglandin analogs and prostamides especially in high-risk eyes.
Esquenazi
Salomon
S
Department of Ophthalmology, LSU Eye and Neuroscience Center of Excellence, New Orleans, LA 70112, USA. sesque@lsuhsc.edu
D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008269:Macular Edema / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000627:therapeutic use; D019591:Pseudophakia / Q000150:complications* / Q000188:drug therapy; D011810:Quinoxalines / Q000627:therapeutic use; D041623:Tomography, Optical Coherence / Q000379:methods; D000069557:Travoprost; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D003008:Cloprostenol; D000068438:Brimonidine Tartrate; D000077338:Latanoprost; D011239:Prednisolone; D000069557:Travoprost